Lora B. Kramer

1.5k total citations
34 papers, 1.2k citations indexed

About

Lora B. Kramer is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Lora B. Kramer has authored 34 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 14 papers in Hematology and 7 papers in Oncology. Recurrent topics in Lora B. Kramer's work include Histone Deacetylase Inhibitors Research (10 papers), Cell death mechanisms and regulation (9 papers) and Multiple Myeloma Research and Treatments (7 papers). Lora B. Kramer is often cited by papers focused on Histone Deacetylase Inhibitors Research (10 papers), Cell death mechanisms and regulation (9 papers) and Multiple Myeloma Research and Treatments (7 papers). Lora B. Kramer collaborates with scholars based in United States, Canada and Russia. Lora B. Kramer's co-authors include Steven Grant, Yun Dai, Paul Dent, Shuang Chen, Mohamed Rahmani, W. David Jarvis, Xin‐Yan Pei, Rebecca S. Traylor, Heather Martin and Frank A. Fornari and has published in prestigious journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

In The Last Decade

Lora B. Kramer

34 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lora B. Kramer United States	22	871	298	230	103	98	34	1.2k
Kee Chuan Goh Singapore	16	596 0.7×	389 1.3×	119 0.5×	85 0.8×	158 1.6×	26	1.1k
João Agostinho Machado‐Neto Brazil	22	775 0.9×	200 0.7×	295 1.3×	204 2.0×	212 2.2×	149	1.3k
Xiao-Feng Le United States	21	910 1.0×	462 1.6×	132 0.6×	99 1.0×	29 0.3×	23	1.3k
David W. End United States	15	631 0.7×	301 1.0×	301 1.3×	49 0.5×	131 1.3×	26	1.1k
Silvia Fernández de Mattos Spain	18	1.1k 1.3×	355 1.2×	114 0.5×	79 0.8×	136 1.4×	31	1.6k
Jay Mei United States	13	451 0.5×	236 0.8×	204 0.9×	28 0.3×	110 1.1×	47	808
Xianping Shi China	20	683 0.8×	261 0.9×	154 0.7×	72 0.7×	80 0.8×	35	1.0k
Tríona Ní Chonghaile Ireland	15	758 0.9×	301 1.0×	243 1.1×	164 1.6×	80 0.8×	37	1.3k
Olusegun Williams United States	7	996 1.1×	191 0.6×	79 0.3×	129 1.3×	304 3.1×	7	1.3k
Magdalena Bachvarova Canada	22	718 0.8×	245 0.8×	110 0.5×	78 0.8×	249 2.5×	35	1.2k

Countries citing papers authored by Lora B. Kramer

Since Specialization

Citations

This map shows the geographic impact of Lora B. Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lora B. Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lora B. Kramer more than expected).

Fields of papers citing papers by Lora B. Kramer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lora B. Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lora B. Kramer. The network helps show where Lora B. Kramer may publish in the future.

Co-authorship network of co-authors of Lora B. Kramer

This figure shows the co-authorship network connecting the top 25 collaborators of Lora B. Kramer. A scholar is included among the top collaborators of Lora B. Kramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lora B. Kramer. Lora B. Kramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Liang, Yu Zhang, Yun Leng, et al.. (2019). The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo. Journal of Hematology & Oncology. 12(1). 25–25. 22 indexed citations

Dai, Yun, Shuang Chen, Liang Zhou, et al.. (2014). Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells. PLoS ONE. 9(3). e89064–e89064. 23 indexed citations

Chen, Shuang, Yun Dai, Li Wang, et al.. (2012). CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies. Cancer Research. 72(16). 4225–4237. 46 indexed citations

Nguyen, Tri, Yun Dai, Elisa Attkisson, et al.. (2011). HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo. Clinical Cancer Research. 17(10). 3219–3232. 70 indexed citations

Dai, Yun, Shuang Chen, Li Wang, et al.. (2011). Disruption of IκB Kinase (IKK)-mediated RelA Serine 536 Phosphorylation Sensitizes Human Multiple Myeloma Cells to Histone Deacetylase (HDAC) Inhibitors. Journal of Biological Chemistry. 286(39). 34036–34050. 32 indexed citations

Dai, Yun, Shuang Chen, Li Wang, et al.. (2011). Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF‐κB and Bim. British Journal of Haematology. 153(2). 222–235. 55 indexed citations

Kramer, Lora B., et al.. (2009). MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia. 23(10). 1744–1754. 43 indexed citations

Dasmahapatra, Girija, Mohamed Rahmani, Lora B. Kramer, et al.. (2009). BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biology & Therapy. 8(9). 808–819. 28 indexed citations

Dai, Yun, et al.. (2008). Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells. Clinical Cancer Research. 14(2). 549–558. 68 indexed citations

10.

Pei, Xin‐Yan, Yun Dai, Shuang Chen, et al.. (2008). The MEK1/2 inhibitor AZD6244 (ARRY-142886) interacts synergistically with the novel Chk1 inhibitor AZD7762 to induce apoptosis in human multiple myeloma cells. Cancer Research. 68. 3 indexed citations

11.

Gao, Ning, Lora B. Kramer, Mohamed Rahmani, Paul Dent, & Steven Grant. (2006). The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 through a Transcriptional Mechanism. Molecular Pharmacology. 70(2). 645–655. 38 indexed citations

12.

Rahmani, Mohamed, Yun Dai, Lora B. Kramer, et al.. (2004). Cotreatment with Suberanoylanilide Hydroxamic Acid and 17-Allylamino 17-demethoxygeldanamycin Synergistically Induces Apoptosis in Bcr-Abl+ Cells Sensitive and Resistant to STI571 (Imatinib Mesylate) in Association with Down-Regulation of Bcr-Abl, Abrogation of Signal Transducer and Activator of Transcription 5 Activity, and Bax Conformational Change. Molecular Pharmacology. 67(4). 1166–1176. 70 indexed citations

13.

Rahmani, Mohamed, Yun Dai, Lora B. Kramer, et al.. (2004). Co-Administration of SAHA and 17-AAG Synergistically Induces Apoptosis in Bcr-Abl+ Cells Sensitive and Resistant to STI-571 in Association with Down-Regulation of Bcr-Abl, Abrogation of STAT5 Activity, and Bax Conformational Change.. Blood. 104(11). 1995–1995. 1 indexed citations

14.

Decker, Roy H., Jay M. Levin, Lora B. Kramer, Yun Dai, & Steven Grant. (2003). Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[β-d-arabinofuranosyl]cytosine (ara-C)-induced apoptosis. Biochemical Pharmacology. 65(12). 1997–2008. 7 indexed citations

15.

Harvey, S., R. H. Decker, Yun Dai, et al.. (2001). Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.. PubMed. 7(2). 320–30. 20 indexed citations

16.

Vrana, Julie A., et al.. (1999). Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells. Biochemical Pharmacology. 58(1). 121–131. 19 indexed citations

17.

Wang, Shujie, Julie A. Vrana, Alex J. Freemerman, et al.. (1997). Agents that Down-Regulate or Inhibit Protein Kinase C Circumvent Resistance to 1-β-D-Arabinofuranosylcytosine-Induced Apoptosis in Human Leukemia Cells that Overexpress Bcl-2. Molecular Pharmacology. 52(6). 1000–1009. 68 indexed citations

18.

Turner, Amy, et al.. (1996). Modulation of Protein Kinase C Activity and Calcium-Sensitive Isoform Expression in Human Myeloid Leukemia Cells by Bryostatin 1: Relationship to Differentiation and Ara-C-Induced Apoptosis. Experimental Cell Research. 228(1). 65–75. 24 indexed citations

19.

Ghosh, Shobha, Lora B. Kramer, John D. Schuetz, et al.. (1995). Renal and hepatic family 3A cytochromes P450 (CYP3a) in spontaneously hypertensive rats. Biochemical Pharmacology. 50(1). 49–54. 33 indexed citations

20.

Ghosh, Soumitra, et al.. (1995). Maternal environment defines blood pressure and its response to troleandomycin in spontaneously hypertensive rats. American Journal of Hypertension. 8(3). 321–324. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact